Quick take: Yong Tai rises 9% in active trade

KUALA LUMPUR: Shares of Yong Tai Bhd attracted strong trading interest in early trade Friday, rising over 9%.

The counter rose 9.43%, or 2.5 sen to 29 sen. It is currently the second most active counter on Bursa Malaysia with 182 million shares done.

Yong Tai’s subsidiary, YTB Healthcare Sdn Bhd (YTBH), has secured approval for the clinical trial import licence from the National Pharmaceutical Regulatory Agency (NPRA), allowing it to conduct Phase 3 clinical trials for Covid-19 vaccine in Malaysia.

It said the approval granted by NPRA to YTBH followed the earlier approval received from the Medical Review Ethics Committee (MREC).

Yong Tai said its strategic partner Shenzhen Kangtai Biological Products Co Ltd (SZKT) has been granted the emergency use authorisation (EUA) by the government of China recently for developing the inactivated Covid-19 vaccine (KCONVAC).

SZKT commenced its KCONVAC vaccination programme in China, with its first batch of vaccination programme of more than 500,000 doses on June 1.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Yong Tai , Shenzhen Kangtai


Next In Business News

Trading ideas: Southern Steel, Tanco, Bina Darulaman
China Evergrande inches close to default deadline, investors wait
US agency confirms air bag safety probe into 30 million vehicles
India's summer grains output seen at record 150.50 mln tonnes in 2021/22
Stocks steady as markets calm after Evergrande-led slide
Oil edges up, as investors worry about global demand
Vibrant capital market in the works
UK public borrowing falls less than expected as debt costs rise
The critical role of banks in economic recovery
Astro Q2 net profit at RM87mil

Stories You'll Enjoy